onepharm, a Viennese biotech company specializing in the development of new antiviral drugs, has been awarded funding of over 3.5 million euros. “With this funding and our outstanding team, which now numbers 10 staff and experts, our projects in the development of new drugs to combat viral respiratory tract diseases are now right on track” enthused Dr. Bernhard Küenburg, CEO of onepharm.
